Please ensure Javascript is enabled for purposes of website accessibility

Why Aerie Pharmaceuticals Dropped 12% Today

By Todd Campbell - Sep 21, 2015 at 4:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Aerie Pharmaceuticals is enrolling patients in a phase 3 study for its glaucoma drug Roclatan.

Source: Aerie Pharmaceuticals

What: Despite reporting that its kicked-off its phase 3 trial of Roclatan, a therapy that treats glaucoma, shares in Aerie Pharmaceuticals (AERI -4.62%) tumbled by 12% today.

So what: Roclatan is Aerie Pharmaceuticals next-generation therapy for reducing intraocular pressure in patients with eye disorders, including glaucoma.

Earlier this month, Aerie Pharmaceuticals announced its timeline for an FDA filing for approval of its most advanced candidate, Rhopressa, a drug that matched up to the efficacy of timolol, a long-standing current therapy.

Assuming that safety data that will be coming next year for Rhopressa is solid, Aerie Pharmaceuticals plans to file for FDA approval in the first half of 2016, which could allow it to launch Rhopressa commercially in 2017.

Roclatan is a fixed-dose combination therapy comprising Rhopressa and latanoprost, a prostaglandin analogue therapy that is already being used in this patient population.

In phase 2 trials, Roclatan demonstrated superiority to both Rhopressa and latanoprost, indicating the potential for Roclatan to be the best-in-class therapy option for glaucoma patients.

Now what: Rhopressa has an opportunity to make it to the market more quickly, but Roclatan could end up moving the needle more.

Earlier this year, Rhopressa failed to achieve its primary endpoint in one phase 3 trial, which led to a reconfiguring of the addressable patient population to include only those with intraocular pressure below 26 mmHg for its other phase 3 trial, which succeeded. As a result, Rhopressa -- if approved -- may not be suitable for up to 20% of all glaucoma patients.

Roclatan, however, will be studied in a larger patient pool that includes people with intraocular pressure below 36 mmHg and as a result, if its trials are successful, then it could address most glaucoma patients. Efficacy results from Roclatan's phase 3 trial are expected in about a year, with full safety results likely to come later.

Since it will be a while before we know if Roclatan works, investors should probably focus more on Rhopressa's opportunity than Roclatan. Because glaucoma is a potential billion dollar treatment market, risk tolerant investors might want to keep Aerie Pharmaceuticals on their radar.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aerie Pharmaceuticals, Inc. Stock Quote
Aerie Pharmaceuticals, Inc.
AERI
$6.81 (-4.62%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.